Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

Company Overview

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.01 to $0.03
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 6.08 million shs
• Market Capitalization: $7.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SGYP Stock Analysis - Frequently Asked Questions

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million.

What other stocks do shareholders of Synergy Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Westmoreland Coal (WLB), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 11/08/2018
• Today: 8/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SGYP
• CIK: 1347613
• Web: www.synergypharma.com
• Phone: 212-297-0020
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$224.33 million
• Net Margins: -332.11%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -118.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.52
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: $16.82 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 248,040,000
• Free Float: N/A
• Market Cap: $7.44 million
• Optionable: Optionable
• Beta: 4.94